(631) 444-2600
- Specialty:
Subspecialty:
- Pathology
Hematopathology
- Administrative/ Clinical Title:
- Medical Director, Flow Cytometry Laboratory
YUPO MA MD, PHD
For Appointments:
(631) 444-2600
CANCER
CLINICAL PATHOLOGY
HEMATOPATHOLOGY
LEUKEMIA
LYMPHOMA
PATHOLOGY
PATHOPHYSIOLOGY
1199NBF
AETNA
AFFINITY HEALTH PLAN
BEECH STREET
CIGNA GREAT WEST HEALTHCARE
CIGNA HMO
CIGNA PPO
EMPIRE BLUE CROSS HMO
EMPIRE BLUE CROSS OTHER PLANS
EMPIRE BLUE CROSS PPO
EMPIRE BLUE CROSS SENIOR PLAN
FIDELIS CARE NEW YORK
GHI CBP
GHI HMO
HEALTHFIRST
HIP
ISLAND GROUP ADMINISTRATION
MEDICAID
MEDICARE
MULTIPLAN
MULTIPLAN PHCS
MULTIPLAN SAVILITY
NEIGHBORHOOD HEALTH PLAN
NO FAULT
SUFFOLK HEALTH PLAN
UNITED EMPIRE PLAN (NYSHIP)
UNITED HEALTHCARE
UNITED OXFORD FREEDOM PLAN
US FAMILY HEALTH PLAN
VYTRA (except SMART START)
WORKERS COMP
Education & Training
- Medical Degree:
- Jinan University College of Medicine, P.R. China
- Residency:
- Pathology, Brown University, RI
- Fellowship:
-
Hematopathology, MD Anderson Cancer Center, TX
Academic & Other
- Teaching Activity:
- Pathology
- Year Appointed at
Stony Brook:
- 2010
Best Research Scientist in Las Vegas, selected by In Business Las Vegas; 2009
NIH Career Development Award; 2003 - 2008
Member of:
The College of American Pathology
American Society of Hematology
- Clinical Practice Began:
- 2002
Locations
-
PATHOLOGY
UNIVERSITY MEDICAL CENTER,
NICOLLS ROAD,
STONY BROOK,
NY 11794-7025.
Selected Publications
1. Tian E, Zhang F, Walker R, Rasmussen E, Ma Y, Barlogie B and Shaughnessy JD. The Role of the Wnt/b-catenin Signaling Antagonist DKK1 in Development of Osteolytic Lesions in Multiple Myeloma. New Engl J. MED. 2003, Dec 25; 349(26): 2483-94.
2. L Chai, Yang J, Di C, Cui W, Lai R, and Ma Y. Transcriptional activation of the SALL1 by the human SIX1 domain. 2006, J. Biol. Chem. 14;281(28):18918-26.
3. Ma Y, Wei C, Yang J, Qu J, Di C , Amin HM, Lai R, Ritz J, Krause DS, and L Chai. SALL4, a novel oncogene, is constitutively expressed in acute myeloid leukemia (AML) and is sufficient to induce AML in transgenic mice. 2006, Blood , Oct 15;108(8):2726-35.
4. Zhang J, Tam W, Tong GQ, Wu Q, Chan BS, Lou Y, Yang J, Ma Y, Chai L, Ng H, Lufkin T, Robson P and B Lim. Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. 2006 Nature Cell Biology, 2006 Oct;8(10): 1114.
5. Yang J, Chai L, Liu F, Flink L,Pei L, Siberstain L, Amin, HM, Ward D, and Ma Y. Bmi-1 is a SALL4 Target Gene for SALL4 in Hematopoietic and Leukemic Cells. 2007, Proc. Natl. Acad. Sci. USA.104:10494-10499
6. Yang Y, Chai L, Fowles T, Alipio Z, Fink LM, Ward DC and Ma Y SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood, 2008 Aug 1;112(3):805-13. Epub 2008 May 16.
7. Yang Y, Chai L, Fowles T, Alipio Z, Fink LM, Ward DC and Ma Y. Genome-wide analysis reveals Sall4 to be a key master regulator of pluripotency in murine embryonic stem cells. 2008, Proc. Natl. Acad. Sci. USA. Dec 16;105(50):19756-61. Epub 2008 Dec 5
8. Xu D, Alipio Z, Fink LM, Adcock DM, Yang Y, Ward DC, Ma Y. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy, 2009, Proc. Natl. Acad. Sci. USA.Jan 20;106(3):808-13.
9. Wang P, Wu F, Ma Y, Li L, Lai R, Young L. Functional Characterization of the kinase activation loop in nucleophosmin (NPM) -anaplastic lymphoma kinase (ALK)using tandem affinity purification and liquid chromatography-mass spectrometry, J Biol Chem 2009 Nov 2. [Epub ahead of print].
10. Gai H, Nguyen DV, Moon YJ, Aguila JR, Fink LM, Ward DC, Ma Y. Generation of Murine Hepatic Lineage Cells from Induced Pluripotent Stem Cells. 2010, Differentiation. 79(3):171-81.
11. Yang Y, Chai L, Ma Y. A novel SALL4/OCT4 transcriptional regulation feedback loop in embryonic stem Cell, PLoS One. 2010 May 21;5(5):e10766.
12. Alipio Z, Liao W, Roemer EJ, Waner M, Fink LM, Ward DC, Ma Y. Reversal of Hyperglycemia in Diabetic Mouse Models using iPS derived Pancreatic Beta-Like Cells. 2010 Proc Natl Acad Sci U S A. 2010 Jul 7.
[Epub ahead of print]
Personal Statement
There are 700 + physicians and other health care providers practicing within 18 different clinical entities, or specialty groups that are affiliated with Stony Brook University Physicians (SBU Physicians). Together, these providers offer patients of all ages a comprehensive range of high quality medical services, from primary care to advanced specialty care. The physicians and health care professionals affiliated with SBU Physicians are committed to excellence in service and leadership in clinical care. In their capacity as faculty of the Stony Brook University School of Medicine, they also educate medical students, interns, residents and fellows in many specialties and sub-specialties, and engage in research and clinical trials that help to advance the science of medicine.
These physicians and health care professionals are committed to excellence in service and leadership in clinical care for their patients. SBU Physicians supports and coordinates this mission and maintains this website for patients, physicians and staff.
